Jaime W. Vieser - 29 Sep 2021 Form 4 Insider Report for ZIOPHARM ONCOLOGY INC (TCRT)

Role: Director
Signature: /s/ Kevin Lafond, Attorney-in-Fact
Issuer symbol: TCRT
Transactions as of: 29 Sep 2021
Net transactions value: +$191,000
Form type: 4
Filing time: 04 Oct 2021, 18:11:27 UTC
Next filing: 24 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TCRT	Common Stock	Purchase	$191,000	+100,000	+17%	$1.91	705,321	29 Sep 2021	Direct	F1
holding	TCRT	Common Stock						100,000	29 Sep 2021	By UTMA for child
holding	TCRT	Common Stock						75,000	29 Sep 2021	By UTMA for child
holding	TCRT	Common Stock						75,000	29 Sep 2021	By UTMA for child
holding	TCRT	Common Stock						75,000	29 Sep 2021	By UTMA for child

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.90 to $1.96 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.90 to $1.96 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.